Janssen-Cilag places first in the “Best Pharmaceutical Companies” 2022 ranking in Germany in the category “Research-based global leaders by sales”. Janssen-Cilag also wins the award for innovation and sustainability “The Golden Tablet” 2022 of the urologists. The runner-up places here went to Bayer and Apogepha. Janssen-Cilag’s latest innovation in the field of urology is Erleada® with the approval extension for metastatic hormone-sensitive prostate carcinoma. Janssen is developing the COVID-19 vaccine Jcovden.
Janssen-Cilag – sophisticated and broad portfolio
The award “The Golden Tablet” of the urologists goes in 2022 – as in the two previous years – to Janssen-Cilag. The research-based pharmaceutical company with headquarters in Neuss won 41% of the specialist votes. The next places went to two new finalists: Bayer won 16% of the votes, Apogepha 6%. Janssen-Cilag stood out from the competition in particular due to the highly rated competence of its sales force (46%), the quality of its products (44%), its numerous innovations (39%) and its offer for further education and training (34%). The urologists also rated well the focus on therapeutic areas (29%), the research activity with a large product pipeline (24%), as well as the service offer for the practice (22%).
Janssen-Cilag GmbH is a research-based pharmaceutical company that emerged from Cilag Chemie, founded in 1936, and Janssen Pharmaceutica N.V., founded by the chemist and physician Paul Janssen in Belgium in 1953. In 1996, Cilag Chemie and Janssen merged to form today’s Janssen-Cilag GmbH. The company is part of the world’s largest healthcare group Johnson & Johnson, which is divided into the Pharmaceuticals, Consumer Health and Medical Technology divisions.
The pharmaceutical division achieved total sales of USD 52.1 billion in 2021, of which USD 28 billion was in the USA. Janssen-Cilag employs around 45,000 people worldwide. In Germany, around 1,000 employees generated sales of 2.17 billion euros in 2020.
Janssen-Cilag conducts research in the fields of cardiovascular and metabolism, oncology, immunology, infectiology, neurology/psychiatry and gastroenterology. With the acquisition of the biopharmaceutical company Actelion, the rather rare pulmonary hypertension is also in focus. The COVID-19 vaccine Jcovden (COVID-19 Vaccine Janssen/Ad26.COV2.S) was the only COVID vaccine approved for single use only in basic immunisation. It generated revenues of USD 2.4 billion in 2021. Other top-selling drugs from Janssen-Cilag include Stelara (inflammatory bowel disease), Remicade (rheumatic diseases), Darzalex (multiple myeloma), Invega (schizophrenia). In 2020, urologists in Germany voted Erleada® (prostate cancer) into first place for the “Most Innovative Product” award. It only received the approval extension for metastatic hormone-sensitive prostate carcinoma at the beginning of 2020.
Janssen plans 20 new medicines and indication expansions by 2023. Research and development expenses amounted to USD 11.88 billion in 2021, or 22.8% of sales.
A special area of research at Janssen-Cilag is the concept of disease interception. This approach aims to explore ways to stop diseases before they develop. The concept starts before classical prevention: The aim is to detect disease processes with the help of validated biomarkers before clinical symptoms arise.
Janssen-Cilag relies on a diverse workforce. The company promotes the personal and professional development of its employees through a wide range of qualification programmes. Janssen supports its employees in Germany with flexible working time models such as part-time, home office or job sharing, as well as its own day care centre.
What counts are quality, training and further education, a broad product range and the focus
The awards, which have been presented since 2000, stand for the innovative strength and sustainability of pharmaceutical companies and the progress and benefit of new medicinal products in the evaluation by users. The decisive factors for the award “The Golden Tablet” for the urologists 2022 were overall the quality of the products (46%), the competence of the sales force (35%), the many innovations (33%), the offer of further education and training (33%) and the research activity with a large product pipeline (26%).
Multiple awards for Janssen-Cilag
Erleada®, awarded in 2020, is already the seventh product from Janssen-Cilag to receive the award “The Most Innovative Product”: Invega® was honoured with this award for the first time in 2008, followed by Priligy® (2010 and 2009), Zytiga® (2013, 2012), Imbruvica® (2015) and Tremfya® in 2018 as well as Stelara® (2020, 2019, 2017). Janssen-Cilag received the first “Golden Tablet” award in 2001.
Awards for Janssen-Cilag since 2000:
- The Golden Tablet (2022-2020, 2016, 2013, 2010-2006, 2002, 2001)
- Erleada® (2021, 2020)
- Imbruvica®(2015)
- Invega®(2008)
- Priligy®(2010, 2009)
- Stelara®(2020, 2019, 2017)
- Tremfya® (2018)
- Zytiga® (2013, 2012)
